跳至主要内容
临床试验/ACTRN12621001185853
ACTRN12621001185853已完成2 期

A prospective, multi-centre, single-arm diagnostic phase 2 open-label trial to assess additional diagnostic benefit of FDG PET/CT imaging after staging with PSMA PET for newly diagnosed high grade prostate cancer prior to treatment

Metro North Hospital and Health Service0 个研究点目标入组 32 人开始时间: 2021年9月3日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • 1. Men aged 18 years or older
  • 2. Untreated, histologically confirmed prostate cancer
  • 3. High risk disease according to clinical features, at least one of;
  • - Serum PSA >20ng/ml
  • - Biopsy Gleason Grade 4+4 or higher / Grade Group 4 or higher
  • - cT3/4 according to digital rectal examination (DRE) and/or magnetic resonance imaging (MRI)
  • 4. Negative, Localised or metastatic disease according to PSMA PET/CT
  • 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • 6. Adequate haematological, renal, hepatic and pulmonary functions
  • 7. Written informed consent provided
  • 8. Willingness and ability to comply with all study protocols

排除标准

  • 1. prior treatment with radiotherapy or systemic therapies (e.g. androgen deprivation therapy, chemotherapy) for prostate cancer for longer than 21 days
  • 2. history of other active malignancy within last 2 years (except non-melanoma skin cancer and superficial bladder cancer)
  • 3. severe active co-morbidity or other barrier to completing study processes

研究者

相似试验